News & Analysis on Contract Research, Manufacturing & Clinical Trials
BioClinica bites back at Nicusa Capital's call for leadership changes
By Alexandria Pešić and Claire Videau
- Last updated on
Mark Weinstein, CEO of Bioclinica, has hit back at a public letter from Nicusa Capital CEO, Paul Johnson, claiming that the company's corporate strategy is 'flawed' and demanding the resignation of three top executives.
In an exclusive interview with Outsourcing Pharma, Mr Weinstein explains why he believes he and his collegues were singled out for criticism, and sheds some light on where the battle lines have been drawn in the ongoing dispute.